Home Platform Services Customers Security Company

Turn weeks of manual research into answers in minutes.
Powered by AI agents, backed by experts.

The trusted companion for pharmaceutical Pricing & Market Access teams.

Bayer Gilead and Kite Chiesi Lundbeck Genmab Kyowa Kirin
...and many more
...and many more
0% churn
Since launch
8 of top 20
Pharma companies use Cellbyte
97% 
User satisfaction*
*Based on user satisfaction survey in July/August 2026

Two ways to work with Cellbyte

Platform
Your team, supercharged by AI.
Give every analyst the reach of a global access function. From the first comparator question to the final pricing analysis, your team works across markets in one shared workspace, built on our proprietary clinical, regulatory, HTA and pricing database.
Research in plain language
Every output traceable to source
Automate complex, recurring workflows
Explore the platform →
Services
Our experts, delivering for you.

Life sciences experts combine deep domain knowledge with applied AI to solve complex Pricing & Market Access questions. Comprehensive evidence reviews, expert analysis and clear recommendations - in a fraction of the time traditional research takes.

Expert-led from scoping to delivery
Decision-ready, fully sourced deliverables
Delivered in days, not months
Expert deliverableDisease landscaping · NMOSD
Export
00 Background 01 Unmet need 02 Pathways 03 Comparators 04 Deep-dive 05 HTA 06 Pricing 07 Price dev. References
Section 05
HTA outcomes across five markets

Four EMA-approved options coexist with off-label immunosuppression; label boundaries, comparative evidence and monitoring requirements govern access.8,9,33 Every claim links to its primary source.31

Market
Outcome
Access condition
Germany
Minor added benefit
AQP4-IgG+ label only
France
ASMR IV
Relapsing, ≥ 2 prior lines
+ more markets
Explore services →

Discover how Cellbyte transforms your outcomes

Case study · Lilly Deutschland · Oncology · 521 procedures

Assessing the impact of biomarker status on benefit ratings and evidence confirmation

Rating mix by biomarker status
Major
Consid.
Minor
Non-q.
None
Biomarker n=237No biomarker n=284
2 weeks8 weeks−75%Research time
Read case study →
ISPOR Europe 2026 Presenter

Published at ISPOR Europe 2026

German HTA added-benefit outcomes for biomarker-based drug therapies in oncology
View abstract ↗
“

Cellbyte saved me so much time. I can quickly check the sources and the specific passage where the AI found certain information.

Senior Manager · Global Pricing & Market Access, Top-20 Pharma
Case study · Top-20 pharma · Oncology

Assessing the impact of OS length on benefit rating and pricing outcomes

Benefit-rating mix by OS gain
None
Small
Mod.
Subst.
Large
OS gain →Stronger G-BA rating
8 hours3 weeks−93%Research time
Read case study →
Discover customer case studies →

What Pricing & Market Access teams
use Cellbyte for

Pharma runs on trust. So do we.

GDPR EU compliant
GDPR EU Compliant
ISO/IEC 27001:2022 certified
ISO/IEC 27001:2022 Certified
SOC 2 Type II
SOC 2 Type II
Audit in progress
See security & compliance →

Your next Pricing & Market Access question, answered in minutes

Experience Cellbyte on an indication you're actually working on.

Book a demo